StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

Analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Friday. The firm set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of OGEN stock opened at $0.35 on Friday. Oragenics has a fifty-two week low of $0.35 and a fifty-two week high of $7.74. The firm has a market cap of $1.98 million, a P/E ratio of -0.05 and a beta of 0.45. The business’s 50 day moving average price is $0.79 and its 200-day moving average price is $1.18.

Oragenics (NYSE:OGEN) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC purchased a new position in Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.